Randomized Trialmoderate evidence
N-Acetylgalactosamine-Conjugated Small Interfering RNA Targeting Hepatic Angiotensinogen in Hypertension: A Phase I Clinical Trial With Randomized Part A and Open-Label Part B.
JAMA cardiology·October 30, 2026·PMID 42961436
Why it mattersHypertension management often requires daily medication, and adherence is poor. A long-acting siRNA that durably suppresses angiotensinogen could offer a novel treatment paradigm with infrequent dosing, potentially improving blood pressure control and reducing cardiovascular risk.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled